ANNEXIN-A1 MIMETICS: A NOVEL THERAPEUTIC APPROACH FOR TARGETING THE CARDIAC COMPLICATIONS OF DIABETES

ANNEXIN-A1 模拟物：一种针对糖尿病心脏并发症的新型治疗方法

• 批准号: nhmrc : GNT1081770
• 负责人: Prof Rebecca Ritchie
• 金额: $ 78.42万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/annexin-a1-mimetics-complications-diabetes/1345417
• 关键词: ANNEXIN; A1; MIMETICS; NOVEL; THERAPEUTIC

Diabetes affects almost 2 million Australians, creating an increasing heart failure burden. A/Prof Rebecca Ritchie’s team at Baker IDI are interested in the precise role of cardiac inflammation in the progression of cardiomyopathy resulting from diabetes. Using her exciting discovery that a naturally-occurring anti-inflammatory protein is a key regulator of cardiac muscle cell survival and function, A/Prof Ritchie’s team will develop therapies for diabetic cardiomyopathy based on this protein.

糖尿病影响着近200万澳大利亚人，造成越来越多的心力衰竭负担。贝克IDI的Rebecca里奇教授的团队对心脏炎症在糖尿病引起的心肌病进展中的确切作用感兴趣。利用她令人兴奋的发现，一种天然存在的抗炎蛋白是心肌细胞存活和功能的关键调节因子，A/里奇教授的团队将开发基于这种蛋白质的糖尿病心肌病疗法。